MedTrace Logo

Extended Postoperative Oral Tranexamic Acid in Knee Replacement

NCT05099276 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-03-06

No results posted yet for this study

Summary

A comparison of outcomes between use of oral tranexamic acid as compared to oral placebo in the first days after total knee replacement will be made to determine impact on clinical indications and patient reported outcomes.

Conditions

Interventions

DRUG

Tranexamic Acid Pill

1950 mg tranexamic acid (three capsules) given in post-anesthesia room and three capsules for postop day one and three capsules for postop day two

DRUG

Placebo

Three capsules of cellulose given in post-anesthesia room and three capsules for postop cay one and three capsules for postop day two

Sponsors & Collaborators

  • Campbell Clinic

    lead OTHER

Principal Investigators

  • Marcus C Ford, MD · Campbell Clinic

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2023-12-31
Completion
2024-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05099276 on ClinicalTrials.gov